Table 2 The univariate analysis of neuropathic pain among patients with NMOSD

Female: male (ratio)

33:3(11:1)

42:8 (5:1)

2.21(0.54–8.99)

Age, y, mean ± sd

51.2 ± 13.3

42.5 ± 13.2

1.05(1.02–1.09)

AQP4-IgG-positive, n (%)

34(91.1)

40(81.6)

2.55(0.64–10.18)

Length of spinal cord involvement, mean ± sd^a

5.8 ± 5.0

3.0 ± 3.8

1.16(1.03–1.32)

EDSS, mean ± sd

4.5 ± 2.6

4.0 ± 2.8

1.07(0.9–1.28)

Attack type, n (%)

  Optic neuritis

7(18.9)

20(40.8)

0.34(0.12–0.92)

  Myelitis

32(86.5)

31(63.3)

3.72(1.23–11.24)

  Brain stem

9(24.3)

8(16.3)

1.65(0.57–4.79)

MR lesion type, n (%)^a

  Cervical

19(55.9)

11(33.3)

2.53(0.94–6.83)

  Thoracic

21(61.8)

12(36.4)

2.83(1.05–7.61)

  Lumber

1(2.9)

1(3.0)

0.97(0.06–16.17)

  Brain stem

10(29.4)

8(24.2)

1.3(0.44–3.86)

  Optic

1(2.9)

7(21.2)

0.11(0.01–0.97)

Isolated thoracic, n (%)^a

8(23.5)

5(15.2)

1.72(0.5–5.94)

Upper thoracic lesions, n (%)^a

18(52.9)

9(27.3)

3(1.08–8.32)

Lower thoracic lesions, n (%)^a

13(38.2)

5(15.2)

3.47(1.07–11.24)

≥ 4 thoracic lesions, n (%)^a

15(44.1)

3(9.1)

7.9(2.01–30.95)

≥ 3 spinal lesions, n (%)^a

26(76.5)

14(42.4)

4.41(1.54–12.62)

IVMP, n (%)

32(94.1)

33(82.5)

3.39(0.66–17.58)

Intravenous immunoglobulin, n (%)

12(35.3)

4(10)

4.91(1.41–17.13)

Plasma exchange, n (%)

0(0)

2(5)

0(0–0)

Oral glucocorticoid, n (%)

37(100)

46(93.9)

Inf

AZA, n (%)

19(51.4)

26(53.1)

0.93(0.4–2.19)

MMF, n (%)

9(24.3)

4(8.2)

3.62(1.02–12.86)

Antidepressants, n (%)

9(24.3)

-

-

Antiepileptic, n (%)

32(86.5)

-

-

Antispasticity, n (%)

12(32.4)

-

-

Opioids, n (%)

2(5.4)

-

-